MBMassimiliano Biagini

Massimiliano Biagini

*This is an algorithmically generated author record based on publicly available information.

Massimiliano Biagini has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dissecting the glycoprofile of the human cytomegalovirus protein gB by comprehensive mass spectrometry analysis

    by Antonio Lembo, Gian Luca Sardone, Michela Aurilia, Antonio Molinaro, Francesco Berti, Cristina De Castro, Massimiliano Biagini


  • Open Access

    Evolution of Vaccines Formulation to Tackle the Challenge of Anti-Microbial Resistant Pathogens

    by Francesco Tognetti, Massimiliano Biagini, Maxime Denis, Francesco Berti, Domenico Maione, Daniela Stranges

    The increasing diffusion of antimicrobial resistance (AMR) across more and more bacterial species emphasizes the urgency of identifying innovative treatment strategies to counter its diffusion. Pathogen infection prevention is among the most effective strategies to prevent the spread of both disease and AMR. Since their discovery, vaccines have been the strongest prophylactic weapon against infectious diseases, with a multitude of different antigen types and formulative strategies developed over more than a century to protect populations from different pathogens. In this review, we review the main characteristics of vaccine formulations in use and under development against AMR pathogens, focusing on the importance of administering multiple antigens where possible, and the challenges associated with their development and production. The most relevant antigen classes and adjuvant systems are described, highlighting their mechanisms of action and presenting examples of their use in clinical trials against AMR. We also present an overview of the analytical and formulative strategies for multivalent vaccines, in which we discuss the complexities associated with mixing multiple components in a single formulation. This review emphasizes the importance of combining existing knowledge with advanced technologies within a Quality by Design development framework to efficiently develop vaccines against AMR pathogens.


  • Open Access

    Exploring the Role of GMMA Components in the Immunogenicity of a 4-Valent Vaccine against Shigella

    by Francesca Mancini, Renzo Alfini, Valentina Caradonna, Valentina Monaci, Martina Carducci, Gianmarco Gasperini, Diego Piccioli, Massimiliano Biagini, Carlo Giannelli, Omar Rossi, et al.

    Shigellosis is the leading cause of diarrheal disease, especially in children of low- and middle-income countries, and is often associated with anti-microbial resistance. Currently, there are no licensed vaccines widely available against Shigella, but several candidates based on the O-antigen (OAg) portion of lipopolysaccharides are in development. We have proposed Generalized Modules for Membrane Antigens (GMMA) as an innovative delivery system for OAg, and a quadrivalent vaccine candidate containing GMMA from S. sonnei and three prevalent S. flexneri serotypes (1b, 2a and 3a) is moving to a phase II clinical trial, with the aim to elicit broad protection against Shigella. GMMA are able to induce anti-OAg-specific functional IgG responses in animal models and healthy adults. We have previously demonstrated that antibodies against protein antigens are also generated upon immunization with S. sonnei GMMA. In this work, we show that a quadrivalent Shigella GMMA-based vaccine is able to promote a humoral response against OAg and proteins of all GMMA types contained in the investigational vaccine. Proteins contained in GMMA provide T cell help as GMMA elicit a stronger anti-OAg IgG response in wild type than in T cell-deficient mice. Additionally, we observed that only the trigger of Toll-like Receptor (TLR) 4 and not of TLR2 contributed to GMMA immunogenicity. In conclusion, when tested in mice, GMMA of a quadrivalent Shigella vaccine candidate combine both adjuvant and carrier activities which allow an increase in the low immunogenic properties of carbohydrate antigens.


  • Open Access

    NHBA is processed by kallikrein from human saliva

    by Elisa Pantano, Sara Marchi, Massimiliano Biagini, Martina Di Fede, Vincenzo Nardi-Dei, Silvia Rossi Paccani, Mariagrazia Pizza, Elena Cartocci

    Neisserial Heparin Binding Antigen (NHBA) is a surface-exposed lipoprotein and a component of the Bexsero vaccine. NHBA is characterized by the presence of a highly conserved Arg-rich region involved in binding to heparin and heparin sulphate proteoglycans present on the surface of host epithelial cells, suggesting a possible role of NHBA during N. meningitidis colonization. NHBA has been shown to be cleaved by the bacterial NalP protein, a meningococcal protease and by human lactoferrin (hLF), a host protease present in different body fluids (saliva, breast milk and serum). Cleavage occurs upstream or downstream the Arg-rich region. Since the human nasopharynx is the only known reservoir of infection, we further investigated the susceptibility of NHBA to human proteases present in the saliva to assess whether proteolytic cleavage could happen during the initial steps of colonization. Here we show that human saliva proteolytically cleaves NHBA; and identified human kallikrein 1 (KLK1) as the main protease responsible for this cleavage. Kallikrein is an important enzyme present in blood plasma, lymph, urine, saliva, pancreatic juices, and other body fluids that catalyze the proteolysis of several human proteins. We report the in vitro characterization of NHBA cleavage by kallikrein; the identification of the cleavage in the recombinant NHBA protein and, on the native protein, when expressed on live bacteria. Overall, this findings provide new insights on NHBA as target of host proteases, highlights a potential role of NHBA in the Neisseria meningitidis nasopharyngeal colonization, and of kallikrein as a defensive agent against meningococcal infection.